What does "as low as reasonably achievable" mean for a patient with an initial systolic blood pressure of 174 mm Hg?

ALARA Principle for Blood Pressure of 174 mmHg

For a patient with initial systolic blood pressure of 174 mmHg, "as low as reasonably achievable" (ALARA) means targeting the lowest blood pressure that the patient can tolerate without experiencing adverse effects from treatment, when the standard target of 120-129 mmHg systolic cannot be achieved due to poor tolerability. 1

Understanding ALARA in Context

The ALARA principle is not your first-line target for a patient starting at 174 mmHg. According to the 2024 ESC guidelines, the treatment algorithm should proceed as follows:

Primary Treatment Goals (in order):

1. First objective: Lower BP to <140/90 mmHg in all patients 1
2. Second objective: Target 130/80 mmHg or lower, if well tolerated 1
3. Optimal target: Systolic BP 120-129 mmHg, provided treatment is well tolerated 1

When ALARA Applies:

The ALARA principle is only invoked when the patient cannot tolerate the standard intensive target of 120-129 mmHg systolic. This means:

• The patient experiences significant side effects from BP-lowering medications
• Symptoms such as dizziness, fatigue, or orthostatic hypotension develop
• The patient cannot achieve 120-129 mmHg despite appropriate medication adjustments

In these cases, you target whatever systolic BP the patient can reasonably tolerate while still achieving meaningful BP reduction 1

Practical Application for Your Patient

Starting at 174 mmHg systolic, your approach should be:

Initial Treatment Strategy:

• Start combination therapy immediately (not monotherapy) since BP ≥140/90 mmHg 1
• Preferred combination: RAS blocker (ACE inhibitor or ARB) + dihydropyridine CCB or thiazide diuretic 1
• Use fixed-dose single-pill combinations to improve adherence 1

Target Progression:

1. Aim for <140/90 mmHg first - this is mandatory for all patients
2. Then push toward 120-129 mmHg - this is where you want to be for optimal cardiovascular risk reduction 1
3. Only invoke ALARA if the patient develops intolerance during the titration to 120-129 mmHg

Common Pitfalls to Avoid

Do not prematurely settle for ALARA. The evidence strongly supports intensive BP lowering to 120-129 mmHg for cardiovascular risk reduction 1. ALARA is a fallback position, not a starting point.

Key caveat: The 120-129 mmHg target assumes treatment is well tolerated. The guidelines explicitly recognize increased risk of side effects with intensive treatment 1, so monitor closely for:

• Symptomatic orthostatic hypotension
• Excessive fatigue or weakness
• Electrolyte abnormalities
• Acute kidney injury

Special Populations Where ALARA May Be More Relevant

Consider more lenient targets (potentially invoking ALARA earlier) in:

• Age ≥85 years 1
• Moderate-to-severe frailty 1
• Pre-treatment symptomatic orthostatic hypotension 1
• Limited predicted lifespan (<3 years) 1

For your 174 mmHg patient, unless they fall into one of these special categories, aggressively pursue the 120-129 mmHg target and only back off to ALARA if treatment becomes poorly tolerated.